Michael Amoroso, Precision BioSciences CEO
June 8, 2022 10:15 AM EDTUpdated June 9, 12:15 PM
R&D
Cell/Gene Tx

With eyes on first al­lo­gene­ic CAR-T ap­proval, Pre­ci­sion touts 100% re­sponse in 's­mall niche' pop­u­la­tion

Kyle LaHucik

Senior Reporter

Pre­ci­sion Bio­Sciences has grand reg­u­la­to­ry am­bi­tions for its lead pro­gram: first al­lo­gene­ic CAR-T ther­a­py on the mar­ket, but the biotech will have to shore up …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times